MOLECULAR CHARACTERISTICS AND PROGNOSTIC MARKERS IN ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA (CRITICAL REVIEW)

EXPERIMENTAL & CLINICAL MEDICINE GEORGIA ◽

10.52340/jecm.2021.549 ◽

2021 ◽

Author(s):

TAMAR GODUADZE ◽

GEORGE TEVDORASHVILI ◽

GEORGE BURKADZE

Keyword(s):

Hormone Receptors ◽

Prognostic Markers ◽

Current Knowledge ◽

Intraepithelial Neoplasia ◽

Malignant Progression ◽

Molecular Characteristics ◽

Endometrial Intraepithelial Neoplasia ◽

Gynaecologic Malignancy ◽

Mesenchymal Transformation ◽

Apoptosis Proteins

Endometrial carcinoma represents the most common gynaecologic malignancy, which frequently arises from malignant progression of endometrial intraepithelial neoplasia (EIN). Nowadays, there are no defined prognostic markers for the prognosis of the malignant progression of EIN and it still represents the subject of various investigations. Different studies indicate, that sex hormone receptors, DNA damage and apoptosis proteins, as well as epithelial-mesenchymal transformation markers play an important role in the progression of EIN. However, most of the published studies are full of contradictory results, which indicates that additional studies are necessary. In current review, we will discuss the current knowledge about the mentioned markers in terms of the prognosis of EIN.

Download Full-text

Endometrial hyperplasia (Clinical lecture)

HEALTH OF WOMAN ◽

10.15574/hw.2016.111.10 ◽

2016 ◽

pp. 10-18 ◽

Cited By ~ 2

Author(s):

I.B. Vovk ◽

◽

N.Е. Gorban ◽

O.Ju. Borysiuk ◽

◽

...

Keyword(s):

Key Words ◽

Hormonal Therapy ◽

Endometrial Hyperplasia ◽

Intraepithelial Neoplasia ◽

Diagnosis And Treatment ◽

Pathogenetic Mechanisms ◽

Endometrial Intraepithelial Neoplasia ◽

Mechanisms Of Development ◽

Clinical Lecture

In clinical lecture presents modern views of endometrial hyperplasia in terms of practitioner gynecologist. The problems of classification, pathogenetic mechanisms of development of endometrial hyperplasia. Particular attention is paid to modern approaches to diagnosis and treatment of endometrial hyperplasia. Key words: hyperplasia, endometrium, classification, endometrial hyperplasia, endometrial intraepithelial neoplasia, hormonal therapy.

Download Full-text

Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia

Cancers ◽

10.3390/cancers13112847 ◽

2021 ◽

Vol 13 (11) ◽

pp. 2847

Author(s):

Allison M. Puechl ◽

Daniel Spinosa ◽

Andrew Berchuck ◽

Angeles Alvarez Secord ◽

Kerry E. Drury ◽

...

Keyword(s):

Endometrial Cancer ◽

Single Gene ◽

Intraepithelial Neoplasia ◽

Molecular Classification ◽

Definitive Treatment ◽

Time To Progression ◽

Endometrial Intraepithelial Neoplasia ◽

Definitive Therapy ◽

Patients At Risk ◽

Endometrial Cancers

Background: The aim of this study was to evaluate whether molecular classification prognosticates treatment response in women with endometrial cancers and endometrial intraepithelial neoplasia (EIN) treated with levonorgestrel intrauterine system (LNG-IUS). Methods: Patients treated with LNG-IUS for endometrial cancer or EIN from 2013 to 2018 were evaluated. Using immunohistochemistry and single gene sequencing of POLE, patients were classified into four groups as per the Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE): POLE-mutated, mismatch repair-deficient (MMRd), p53 wild type (p53wt), and p53-abnormal (p53abn). Groups were assessed relative to the primary outcome of progression or receipt of definitive treatment. Results: Fifty-eight subjects with endometrioid endometrial cancer or EIN treated with LNG-IUS were included. Of these, 22 subjects (37.9%) had endometrial cancer and 36 subjects (62.1%) had EIN. Per the ProMisE algorithm, 44 patients (75.9%) were classified as p53wt, 6 (10.3%) as MMRd, 4 (6.9%) as p53abn, and 4 (6.9%) as POLE-mutated. Of the 58 patients, 11 (19.0%) progressed or opted for definitive therapy. Median time to progression or definitive therapy was 7.5 months, with p53abn tumors having the shortest time to progression or definitive therapy. Conclusions: Molecular classification of endometrial cancer and EIN prior to management with LNG-IUS is feasible and may predict patients at risk of progression.

Download Full-text

Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers

Journal of Laboratory Physicians ◽

10.4103/jlp.jlp_58_18 ◽

2018 ◽

Vol 10 (04) ◽

pp. 420-425 ◽

Cited By ~ 1

Author(s):

Taruna Bansal ◽

Nadeem Tanveer ◽

Usha Rani Singh ◽

Sonal Sharma ◽

Navneet Kaur

Keyword(s):

Breast Carcinoma ◽

Hormone Receptors ◽

Prognostic Markers ◽

Binding Protein ◽

Radical Mastectomy ◽

Positive Association ◽

Tumor Stage ◽

Lymph Node Involvement ◽

Clinical Parameters ◽

Node Involvement

Abstract INTRODUCTION: The present histologic and immunohistochemical prognostic markers of breast carcinoma do not effectively identify the subset of patients with poor prognosis. Y-Box binding protein 1 (YB1) is a novel biomarker which may identify and aid in targeted personalized therapy for such patients. MATERIALS AND METHODS: The study was conducted on histopathology specimens of 74 patients of breast carcinoma who had undergone modified radical mastectomy. YB1 immunohistochemistry (IHC) was performed on manual tissue microarray blocks (each having 15 cores). The YB1 expression was quantified in terms of “immunoreactive score” which was correlated with clinical parameters, hormone receptor status, and Her2neu overexpression by IHC. The Her2neu status of the equivocal cases was further evaluated by fluorescent in situ hybridization (FISH). RESULTS: YB1 was positive in 36/74 (48.6%) cases. On IHC and analysis by FISH, 25/74 (34%) cases had Her2neu overexpression. Estrogen receptor (ER) and progesterone receptor (PR) positivity was found in 42% and 36.5% cases, respectively. YB1 immunopositivity was negatively correlated with ER and PR expression, but showed a significant positive correlation with Her2neu expression. No correlation was found with other clinical parameters, tumor stage, and grade, except lymph node involvement, which showed a positive association with YB1 expression. Triple-negative breast carcinoma constituted 25.6% of the total cases, out of which 73.6% were YB1 positive. CONCLUSION: This study found that YB1 has an association with Her2neu expression. It may in future provide a therapeutic target in Her2neu overexpressing tumors.

Download Full-text